UNSPSC 51182016: Alfatradiol

This classification denotes an aromatase inhibitor, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3VQ38D63M7. European Medicines Agency schedules Alfatradiol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12672MIG. Alfatradiol generally arises in the molecular formula C18H24O2. The term ALFATRADIOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 15 no. 3-4, 2001, list 46.) Most nations schedule alfatradiol under HS 29072900 and SITC 51243.

As of Q4 2014, ALFATRADIOL remains the US FDA Preferred Term for this commodity. Alfatradiol bears US NLM identifiers UMLS ID C1957081 and NCI Concept Code C81622. SMILES: CC12CCC3C(C1CCC2O)CCC4=C3C=CC(=C4)O.

UNSPSC 51182016 Alfatradiol (Commodity) covers pharmaceutical products supplied through cooperative purchasing vehicles to state and local government entities, including health departments, correctional facilities, and other public agencies requiring pharmaceutical inventory. State and local governments procure alfatradiol and related generic pharmaceuticals through multistate cooperative agreements that bundle purchasing power across jurisdictions and delegate distribution through established pharmaceutical wholesalers. The issuing bodies are typically state procurement offices administering cooperative purchasing alliances on behalf of multiple member states and municipalities; individual agencies do not solicit separately under this code but instead access framework agreements established at the alliance level. The work involves pharmaceutical manufacturers and distributors meeting cGMP and Drug Supply Chain Security Act compliance, maintaining relationships with authorized wholesalers, and providing detailed product specifications including National Drug Codes, UPCs, and pricing in formats compatible with electronic data interchange systems.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, posted a Request for Proposal on January 20, 2026 (S1070000015802) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products serving participating states including Minnesota and Oregon. The RFP, with proposals due March 26, 2026, requires vendors to supply products through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—and emphasizes price competitiveness (weighted at 75 percent of evaluation), compliance with administrative fee data formats (5 percent), EDI capability (5 percent), fixed pricing (10 percent), and agreement to a 3 percent administrative fee (5 percent). Vendors must carry commercial general liability insurance of $5,000,000 per occurrence and network security and privacy liability of $2,000,000, maintain contractual relationships with at least two of the three wholesalers, and ensure products are available by May 15, 2026 with contracted terms effective July 1, 2026. The contract runs two years for new vendors with optional MMCAP extensions, or aligns with incumbent agreement terms through June 30, 2028.